10/08/2017

P-MAPA plus Gemcitabine against pancreatic cancer

P-MAPA IMMUNOTHERAPY FOR TREATMENT OF PANCREATIC CANCER

Based on experimental data and a scientific rationale, the research network Farmabrasilis announces P-MAPA - an immunotherapy in late-stage development - to be used in association with Gemcitabine for treatment of pancreatic cancer.

P-MAPA immunotherapy associated with Gemcitabine chemotherapy showed a synergistic effect to block tumor progression and increase apoptosis, without additional toxicity, in  experiments using an animal model for study of pancreatic cancer.

The drug association induced the interferon-signaling pathway, specifically IFN-γ, a powerful inducer of tumor cell death.

P-MAPA-treated animals presented 40% of histopathological recovery, expanded to 80% in P-MAPA plus Gemcitabine-treated animals.

 

The complete experimental data and the scientific rationale  for the use of P-MAPA immnotherapy in the treatment of pancreatic cancer may be acessed by the link below (Free PDF files):

Scientific rationale for the use of P-MAPA immunotherapy in the treatment of pancreatic cancer